These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11388708)

  • 1. Vaccine policy decisions: tension between science, cost-effectiveness and consensus?
    Zimmerman RK; Jackson RE
    Am Fam Physician; 2001 May; 63(10):1919, 1923. PubMed ID: 11388708
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
    Rose M; Zielen S
    Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction of pneumococcal vaccine to standard immunisation programmes in Europe: what are we waiting for?
    Heininger U
    Eur J Pediatr; 2002 Dec; 161 Suppl 2():S125-6. PubMed ID: 12494257
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.
    Ray GT; Pelton SI; Klugman KP; Strutton DR; Moore MR
    Vaccine; 2009 Nov; 27(47):6483-94. PubMed ID: 19720366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal conjugate vaccine for young children.
    Zimmerman RK
    Am Fam Physician; 2001 May; 63(10):1991-8. PubMed ID: 11388715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
    Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
    Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is pneumococcal conjugate vaccine needed?].
    Nuorti P
    Duodecim; 2002; 118(1):77-9. PubMed ID: 12229003
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.
    Ray GT; Whitney CG; Fireman BH; Ciuryla V; Black SB
    Pediatr Infect Dis J; 2006 Jun; 25(6):494-501. PubMed ID: 16732146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The heptavalent conjugate pneumococcal vaccine and its implications for managed care--clinical overview and roundtable discussions.
    Alexander PG; Chartrand SA; Davies TJ; Gaines BM; Oster G; Shurin P; Tamsky L; Thornton DK; Wittert W
    Manag Care Interface; 2001; Suppl C():10-28; quiz 29-30. PubMed ID: 11724029
    [No Abstract]   [Full Text] [Related]  

  • 12. Issues in pneumococcal disease and pneumococcal conjugate vaccines: highlights of the 27th meeting of ESPID, Brussels, Belgium, June 9-13, 2009.
    Adam D
    Vaccine; 2009 Nov; 27(50):7133-7. PubMed ID: 19883868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada.
    Poirier B; De Wals P; Petit G; Erickson LJ; Pépin J
    Vaccine; 2009 Nov; 27(50):7105-9. PubMed ID: 19786137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
    Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
    Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
    Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
    Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia.
    Moore D; Bigham M; Patrick D
    Can Commun Dis Rep; 2003 Jun; 29(11):97-104. PubMed ID: 12794969
    [No Abstract]   [Full Text] [Related]  

  • 17. Pneumococcal vaccine recommendations.
    Alper BS
    Am Fam Physician; 2000 Dec; 62(12):2588-9. PubMed ID: 11142467
    [No Abstract]   [Full Text] [Related]  

  • 18. Experience with pneumococcal conjugate vaccine in Norway.
    Aaberge IS
    Expert Rev Vaccines; 2009 Feb; 8(2):159-65. PubMed ID: 19196196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in vaccines and invasive disease in children].
    Moraga Llop FA
    Rev Esp Quimioter; 2001 Dec; 14(4):319-30. PubMed ID: 11856977
    [No Abstract]   [Full Text] [Related]  

  • 20. Pneumococcal vaccine: to vaccinate or to revaccinate--that is the question.
    Uiterwyk SH
    Med Health R I; 2004 Mar; 87(3):68-71. PubMed ID: 15085683
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.